Why Biotech Commercial IT Is Unlike Any Other Industry
The IT challenges facing a pre-commercial biotech preparing to launch its first drug have almost nothing in common with enterprise IT anywhere else. This is the landscape we operate in — exclusively.
The Commercialization Challenge Facing Pre-Commercial Biotech
The biotech industry is producing more first-time drug launches than ever. Nearly 40% of new molecular entities submitted for FDA approval between 2018 and 2023 came from companies with little to no commercialization experience. These companies are developing breakthrough therapies — in rare disease, oncology, neurology, cell and gene therapy — but most have never built a commercial organization before.
The challenge is stark: two-thirds of drug launches fail to meet pre-launch expectations in their first year. The science is often sound. What fails is the commercial infrastructure — the systems, data, technology, and operational readiness that turn an FDA approval into a product on the market.
For pre-commercial biotech, IT is not a support function. It's the backbone of commercial execution. And getting it wrong — or getting it late — can cost millions in lost revenue and competitive positioning.
​
What Makes Biotech Commercial IT Different From Everything Elses​
You're Building Everything From Zero
Unlike enterprise IT where you're optimizing existing systems, pre-commercial biotech starts with nothing. No CRM. No data warehouse. No compliance framework. No IT team. Everything has to be designed, selected, built, validated, and deployed — often in 12–18 months.
The Data Ecosystem Is Uniquely Complex
Prescription data from IQVIA and Symphony Health. Claims data from payers. Hub and distribution data. CRM activity from the field force. Managed care data. All of it flowing in different formats, at different frequencies, requiring tokenization, MDM, and governance before anyone can trust the numbers.
Regulatory and Compliance Pressure Is Constant​​
HIPAA. FDA 21 CFR Part 11. GxP. SOX. Cybersecurity requirements that double every year. A missed compliance requirement doesn't just create risk — it can delay your launch or trigger an audit that consumes months of executive attention.
​
The Timeline Doesn't Move
FDA approval dates don't wait for your IT to be ready. When PDUFA sets an action date, your CRM, data platform, field force technology, and compliance framework all need to be operational. There's no second chance at a launch window.
You Can't Afford to Get Vendor Selection Wrong
eeva vs. Salesforce. IQVIA vs. Symphony Health vs. Komodo. NetSuite vs. Dynamics 365. Every vendor decision locks you into a technology path for years. Choosing wrong — or choosing late — creates rework, delays, and wasted budget that a pre-commercial biotech can't absorb.
Your IT Leader Probably Hasn't Done This Before​​
Most pre-commercial biotechs promote an infrastructure-focused IT director or hire their first IT leader from a large pharma company. Neither has likely built a commercial IT organization from scratch for a first-time launch. The playbook doesn't exist inside the company.
​
The Biotech Companies We Work With
Tailwinds Advisory works exclusively with biotech and life sciences companies. Our typical clients share a common profile:​
Pre-Commercial Biotech (Phase 2/3)
Companies approaching their first U.S. product launch. Typically 50–200 employees, no existing commercial IT infrastructure, and 12–18 months until a potential FDA approval. They need a Fractional CIO to build everything from scratch.
Commercial-Stage Biotech (Post-Launch)​​
Companies that have launched but are scaling — adding indications, expanding the field force, building out analytics, or preparing for a second product. They often need a Program Executive to drive a specific initiative while the IT team runs day-to-day operations.
Specialty & Rare Disease
Companies with small, targeted field forces and complex patient-finding requirements. The data and analytics challenges are different from primary care — precision targeting, HCP identification, and patient journey analytics matter more than scale.
Companies Navigating M&A​​
Biotech companies being acquired, acquiring another company, or integrating post-merger. IT integration — harmonizing systems, data, processes, and teams — is one of the highest-risk workstreams in any M&A transaction.
Therapeutic Areas We've Supported
Tailwinds Advisory has delivered commercial IT across a range of therapeutic areas. The technology architecture and data requirements vary significantly by therapeutic area — a rare disease launch looks nothing like a primary care launch. Our experience spans:​
-
Rare Disease
-
Oncology
-
Specialty Pharma
-
Neurology / CNS
-
Immunology
-
Infectious Disease
-
Ophthalmology / Medical Aesthetics
-
Animal Health
Why Industry Expertise Matters for IT
A generalist IT consulting firm can implement a CRM or build a data warehouse. But they don't understand why MLR review workflows matter for promotional compliance. They don't know that IQVIA data feeds arrive differently than Symphony Health feeds. They don't know which Veeva modules a rare disease launch needs versus an oncology launch. They don't know the PDUFA timeline or what it means for IT readiness.
Tailwinds Advisory operates exclusively in biotech and life sciences because this is an industry where domain expertise isn't a nice-to-have — it's the difference between a successful launch and a failed one. Every engagement is led by a senior executive who has been in these rooms, made these decisions, and delivered these launches.